Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC3111B
- Development stage
- Phase 2
- Lead developer
- GC Biopharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GC3111B is an investigational adult **tetanus, diphtheria, and acellular pertussis vaccine** being developed by GC Biopharma for active immunization against tetanus, diphtheria, and pertussis. It is intended as a domestically developed Tdap vaccine, with GC Biopharma reporting in-house development and production of vaccine antigens and finished product, including a proprietary pertussis-manufacturing process. A Phase I/II study in healthy adults evaluates its safety and immunogenicity versus Boostrix. ([gcbiopharma.com](https://www.gcbiopharma.com/kor/news_view.do?idx=3037))
02
Targets
BCR (Immunoglobulin G B Cell Receptor)TCR-GC3111B (T-cell receptor recognizing influenza peptide–MHC complexes derived from GC3111B antigens)
Beyond the preview
Go deeper on GC3111B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC3111B.